BioWorld

May 5, 2003

View Archived Issues

Repligen Raises $12.5 Privately To Advance Secretin Program

Repligen Corp. raised $12.5 million through a private placement and will use the funds in part for its Phase III product, secretin, also called RG1068. (BioWorld Today) Read More

RNA Tools Company Ambion Gets $10.5 Million In Private Placement

Read More

Pennsylvania Team Makes Eggs,Seems To Abrogate Sacrosanct Embryonic Stem Cells Barrier

Read More

Strong, Predictable Patent Office Needed By Biotech, Pharma Firms

Read More

Other News To Note

Read More

Appointments And Advancements

Read More